Figen Yargucu Zihni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Figen Yargucu Zihni has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Gonca Karabulut
Ege Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı
5 shared publications - Meltem Işıkgöz Taşbakan
Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir, Türkiye
4 shared publications - Şükriye Miray Kilinçer Bozgül
Division of Intensive Care Medicine, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Türkiye
4 shared publications - Devrim Bozkurt
EGE ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI
3 shared publications - Fahrettin Oksel
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
3 shared publications - Gökhan Keser
Department of Internal Medicine, Division of Rheumatology, Ege University School of Medicine, Izmir, Turkey
3 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50314
Dynamic lactate dehydrogenase/lymphocyte ratio and C-reactive protein as predictors of mortality after plasma exchange in ANCA-associated vasculitis
The efficacy of plasma exchange (PLEX) in anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) remains controversial. Early identification of patients unlikely to benefit from PLEX could optimize immunosuppressive strategies. We investigated whether dynamic changes in the lactate dehydrogenase-to-lymphocyte ratio and C-reactive protein (CRP) levels predict in-hospital mortality among critically ill AAV patients undergoing PLEX. In this retrospective, single-center cohort study, 33 adult AAV patients treated with ≥3 PLEX sessions between January 2010 and June 2021 were included. Biochemical parameters were measured immediately before the first and after the final PLEX session. Univariate comparisons between survivors and non-survivors employed Mann–Whitney U and chi-square tests as appropriate. A classification and regression tree (CART) model was constructed, following variable selection, variance inflation factor, and recursive feature elimination, to identify key mortality predictors. Model performance was assessed by the area under the curve (AUC) and cross-validation. Median age was 55 years (range 20–83); 57.6% were male. In-hospital mortality was 39.4% (n = 13). Non-survivors exhibited significantly greater post-PLEX increases in LDH/Ly (median 1.1 vs 0.3; P < .001) and higher final CRP levels (median 10.2 vs 2.8 mg/L; P = .008). The CART model identified post-PLEX LDH-lymphocyte ratio >0.55 as the primary discriminator for mortality, with secondary stratification by CRP > 0.67 mg/dL. The model achieved AUCs of 0.89 (training) and 0.71 (test). Dynamic assessment of LDH-lymphocyte ratio and CRP after PLEX may serve as early, readily available predictors of mortality in critically ill AAV patients. These findings warrant validation in larger, prospective cohorts to refine patient selection for PLEX and tailor adjunctive therapies.
- 21 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (34) , e50314
Open AccessDynamic lactate dehydrogenase/lymphocyte ratio and C-reactive protein as predictors of mortality after plasma exchange in ANCA-associated vasculitis
The efficacy of plasma exchange (PLEX) in anti-neutrophil cytoplasmic antibody–associated vasculitis (AAV) remains controversial. Early identification of patients unlikely to benefit from PLEX could optimize immunosuppressive strategies. We investigated whether dynamic changes in the lactate dehydrogenase-to-lymphocyte ratio and C-reactive protein (CRP) levels predict in-hospital mortality among critically ill AAV patients undergoing PLEX. In this retrospective, single-center cohort study, 33 adult AAV patients treated with ≥3 PLEX sessions between January 2010 and June 2021 were included. Biochemical parameters were measured immediately before the first and after the final PLEX session. Univariate comparisons between survivors and non-survivors employed Mann–Whitney U and chi-square tests as appropriate. A classification and regression tree (CART) model was constructed, following variable selection, variance inflation factor, and recursive feature elimination, to identify key mortality predictors. Model performance was assessed by the area under the curve (AUC) and cross-validation. Median age was 55 years (range 20–83); 57.6% were male. In-hospital mortality was 39.4% (n = 13). Non-survivors exhibited significantly greater post-PLEX increases in LDH/Ly (median 1.1 vs 0.3; P < .001) and higher final CRP levels (median 10.2 vs 2.8 mg/L; P = .008). The CART model identified post-PLEX LDH-lymphocyte ratio >0.55 as the primary discriminator for mortality, with secondary stratification by CRP > 0.67 mg/dL. The model achieved AUCs of 0.89 (training) and 0.71 (test). Dynamic assessment of LDH-lymphocyte ratio and CRP after PLEX may serve as early, readily available predictors of mortality in critically ill AAV patients. These findings warrant validation in larger, prospective cohorts to refine patient selection for PLEX and tailor adjunctive therapies.
- Open Access
- 16 June 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (3) , 667-673
Serum angiopoietin-1 and angiopoietin-2 levels in Turkish patients with Behçet’s disease: associations with clinical manifestations and inflammatory markers
Background/aim: Emerging evidence suggests that dysregulated angiogenesis may contribute to the pathogenesis of Behçet’s disease (BD). This study primarily aimed to investigate serum angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) levels in Turkish patients with BD and compare them with healthy controls. The secondary aims were to compare angiopoietin levels based on clinical manifestations, disease activity, and medication use and to investigate their correlations with age, disease duration, and inflammatory markers. Materials and methods: This cross-sectional study included 56 consecutive patients with BD, diagnosed according to International Study Group criteria, and 56 age- and sex-matched healthy controls. Physical characteristics, clinical manifestations, time since symptom onset, time since diagnosis, medications, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were recorded. Serum Ang-1 and Ang-2 levels were measured by enzyme-linked immunosorbent assay. Comparisons between the two groups were analyzed using the Student t-test or Mann–Whitney U test, and correlations were assessed using Pearson or Spearman correlation coefficients, depending on the data distribution. Results: Serum Ang-1 and Ang-2 levels were significantly higher in patients with BD compared to healthy controls (p < 0.001 and p = 0.031, respectively). Patients with genital ulcers had significantly lower serum Ang-1 levels compared to those without (p = 0.029). Additionally, Ang-2 levels showed moderate positive correlations with CRP (r = 0.518, p < 0.001) and ESR (r = 0.459, p < 0.001). Conclusion: The elevated expression of Ang-1 and Ang-2 in Turkish patients with BD supports the growing evidence of their possible roles in BD pathogenesis.
- 16 June 2026
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 56 (3) , 667-673
Open AccessSerum angiopoietin-1 and angiopoietin-2 levels in Turkish patients with Behçet’s disease: associations with clinical manifestations and inflammatory markers
Background/aim: Emerging evidence suggests that dysregulated angiogenesis may contribute to the pathogenesis of Behçet’s disease (BD). This study primarily aimed to investigate serum angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) levels in Turkish patients with BD and compare them with healthy controls. The secondary aims were to compare angiopoietin levels based on clinical manifestations, disease activity, and medication use and to investigate their correlations with age, disease duration, and inflammatory markers. Materials and methods: This cross-sectional study included 56 consecutive patients with BD, diagnosed according to International Study Group criteria, and 56 age- and sex-matched healthy controls. Physical characteristics, clinical manifestations, time since symptom onset, time since diagnosis, medications, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels were recorded. Serum Ang-1 and Ang-2 levels were measured by enzyme-linked immunosorbent assay. Comparisons between the two groups were analyzed using the Student t-test or Mann–Whitney U test, and correlations were assessed using Pearson or Spearman correlation coefficients, depending on the data distribution. Results: Serum Ang-1 and Ang-2 levels were significantly higher in patients with BD compared to healthy controls (p < 0.001 and p = 0.031, respectively). Patients with genital ulcers had significantly lower serum Ang-1 levels compared to those without (p = 0.029). Additionally, Ang-2 levels showed moderate positive correlations with CRP (r = 0.518, p < 0.001) and ESR (r = 0.459, p < 0.001). Conclusion: The elevated expression of Ang-1 and Ang-2 in Turkish patients with BD supports the growing evidence of their possible roles in BD pathogenesis.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9711-9723
Classification and Regression Tree Analysis in Adult Hemophagocytic Syndrome: Identifying Acute Heart Failure Predictors in ICU Patients
Background: Hemophagocytic syndrome (HPS) is a rare but life-threatening condition often complicated by heart failure (HF). This study aimed to identify predictors of acute heart failure in HPS patients using classification and regression tree (CART) analysis. Methods: A retrospective analysis was performed on 146 HPS patients without a diagnosis of HF. Variables such as age, cardiothoracic ratio (CTR), etiology, N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), ferritin, triglyceride, and lactate dehydrogenase (LDH) levels at diagnosis were included. CART analysis was employed to develop models predicting heart failure status. The model’s performance was evaluated using sensitivity, specificity, and overall accuracy. Results: This study identified several key predictors of acute heart failure in HPS patients. CTR emerged as the most significant predictor, with patients exhibiting a higher ratio being at a greater risk of developing heart failure. NT-proBNP levels and CRP levels were also significant predictors, indicating cardiac stress and systemic inflammation. Age and etiology played crucial roles, with older patients and those with rheumatological causes showing a higher susceptibility to heart failure. The CART models demonstrated good accuracy, with CTR being the most important predictor. Conclusion: This study highlights critical factors, such as CTR, NT-proBNP, CRP levels, age, and etiology in predicting acute heart failure in HPS patients. Early identification of these predictors can facilitate timely interventions, potentially improving outcomes and reducing mortality rates. These findings provide valuable insights for clinical practice and pave the way for further research on acute heart failure management in HPS. Plain Language Summary: HPS is a serious condition that can lead to heart failure, a life-threatening complication. This study aimed to identify factors that predict heart failure in HPS patients to help doctors diagnose and treat it early. By analyzing data from 146 patients, we found that a higher cardiothoracic ratio, elevated NT-proBNP levels, and increased CRP levels were strong predictors of heart failure. These findings mean that doctors can monitor these factors in HPS patients to catch heart failure early and start treatment sooner, potentially saving lives. The study also found that women with HPS might be more likely to develop heart failure, suggesting they need closer monitoring. Overall, this research provides valuable information that can improve patient care and outcomes in HPS.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9711-9723
Open AccessClassification and Regression Tree Analysis in Adult Hemophagocytic Syndrome: Identifying Acute Heart Failure Predictors in ICU Patients
Background: Hemophagocytic syndrome (HPS) is a rare but life-threatening condition often complicated by heart failure (HF). This study aimed to identify predictors of acute heart failure in HPS patients using classification and regression tree (CART) analysis. Methods: A retrospective analysis was performed on 146 HPS patients without a diagnosis of HF. Variables such as age, cardiothoracic ratio (CTR), etiology, N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP), ferritin, triglyceride, and lactate dehydrogenase (LDH) levels at diagnosis were included. CART analysis was employed to develop models predicting heart failure status. The model’s performance was evaluated using sensitivity, specificity, and overall accuracy. Results: This study identified several key predictors of acute heart failure in HPS patients. CTR emerged as the most significant predictor, with patients exhibiting a higher ratio being at a greater risk of developing heart failure. NT-proBNP levels and CRP levels were also significant predictors, indicating cardiac stress and systemic inflammation. Age and etiology played crucial roles, with older patients and those with rheumatological causes showing a higher susceptibility to heart failure. The CART models demonstrated good accuracy, with CTR being the most important predictor. Conclusion: This study highlights critical factors, such as CTR, NT-proBNP, CRP levels, age, and etiology in predicting acute heart failure in HPS patients. Early identification of these predictors can facilitate timely interventions, potentially improving outcomes and reducing mortality rates. These findings provide valuable insights for clinical practice and pave the way for further research on acute heart failure management in HPS. Plain Language Summary: HPS is a serious condition that can lead to heart failure, a life-threatening complication. This study aimed to identify factors that predict heart failure in HPS patients to help doctors diagnose and treat it early. By analyzing data from 146 patients, we found that a higher cardiothoracic ratio, elevated NT-proBNP levels, and increased CRP levels were strong predictors of heart failure. These findings mean that doctors can monitor these factors in HPS patients to catch heart failure early and start treatment sooner, potentially saving lives. The study also found that women with HPS might be more likely to develop heart failure, suggesting they need closer monitoring. Overall, this research provides valuable information that can improve patient care and outcomes in HPS.
- Open Access
- 14 October 2024
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 11 (3) , 364-370
Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study
Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA). Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE). Results: A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb. Conclusion: The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up. Cite this article as: Ediboğlu ED, Çınar M, Kozacı D, et al. Factors associated with the development of anti-drug antibodies to TNFi and the consequences for axial spondyloarthritis; A two-year follow-up study. Eur J Rheumatol. 2024;11(3):364-370.
- 14 October 2024
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 11 (3) , 364-370
Open AccessFactors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study
Objective: To evaluate the development of anti-drug antibodies (ADAb) against tumor necrosis factor inhibitors (TNFi) therapy during a 2-year period and search the factors linked to patients with axial spondyloarthritis (axSpA). Methods: Biologic-naive patients with axSpA were included in this observational study. Serum drug levels and ADAb were measured at weeks 12, 24, 52, and 104 of treatment by enzyme-linked immunosorbent assay (ELISA). The development of ADAb and factors related to ADAb over time were investigated using generalized estimating equations (GEE). Results: A total of 180 patients with axSpA (116 male, mean (±SD) 45.6 (±11.9) years) who started TNFi treatment (etanercept (32.2%), adalimumab (27.2%), golimumab (20.6%), infliximab (20%)) were included. In the etanercept treatment group, only 1 patient had ADAb at 12 weeks and 24 weeks. Anti-drug antibodies against TNFi drugs were present in the adalimumab group in 32.7% of patients and in the infliximab group in 21.2% of patients at 12 weeks, and the proportion of ADAb-positive patients were found to be stable throughout the follow-up for adalimumab- and infliximab-treated patients. In the golimumab group, one patient had ADAb against golimumab at 12 weeks and the proportion of ADAb-positive patients increased throughout follow-up. In longitudinal analysis, baseline age, TNFi type, longitudinal Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and ASDAS-CRP scores, serum C-eeactive protein (CRP) levels, presence of adverse events and treatment discontinuation were associated with the presence of ADAb. Conclusion: The development of ADAb against TNFi therapy is associated with younger age, high disease activity, the development of adverse events and more common treatment discontinuation in patients with axSpA during 2-year follow-up. Cite this article as: Ediboğlu ED, Çınar M, Kozacı D, et al. Factors associated with the development of anti-drug antibodies to TNFi and the consequences for axial spondyloarthritis; A two-year follow-up study. Eur J Rheumatol. 2024;11(3):364-370.
- 20 September 2024
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 12 (3) , 203-209
The Role of Faecal Calprotectin in the Evaluation of Disease Activity in Spondyloarthritis Patients: A Cross-sectional Study
The Role of Faecal Calprotectin in the Evaluation of Disease Activity in Spondyloarthritis Patients: A Cross-sectional Study - Namık Kemal Medical Journal
- 20 September 2024
- Published by Galenos Yayinevi in Namık Kemal Tıp Dergisi
- Vol. 12 (3) , 203-209
The Role of Faecal Calprotectin in the Evaluation of Disease Activity in Spondyloarthritis Patients: A Cross-sectional Study
The Role of Faecal Calprotectin in the Evaluation of Disease Activity in Spondyloarthritis Patients: A Cross-sectional Study - Namık Kemal Medical Journal
- Open Access
- 9 September 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (3) , 474-483
Prevalence of metabolic syndrome patıents with systemic sclerosis
Objective: To determine the prevalence of metabolic syndrome (MetS) in Turkish systemic sclerosis (SSc) patients. Materials and Methods: In this cross-sectional, single-centre study, 76 SSc patients admitted to the outpatient clinic of our tertiary care hospital between July and September 2021 were included. The National Cholesterol Education Programme's Adult Treatment Panel (NCEP-ATP III) criteria were used to define metabolic syndrome (MetS). The relationship between MetS and SSc organ involvement and disease characteristics was investigated. Results: According to the ATP III criteria, 37 cases (48.7%) were identified as having MetS. The prevalance of MetS increased with advancing age (40-45 years: 25%, 46-60 years: 48.4%, >60 years: 62.9%). The cases were divided into two groups according to the presence or absence of MetS. Patients with MetS had higher mean age (58.2±9.4 vs. 51.6±13.5, p=0.015) and lower modified Rodnan skin scores (14 vs. 22, p=0.019). The groups were comparable regarding disease subtype, duration and activity, organs/systems involved and disease-related damage. Conclusion: Although the prevalence of MetS in SSc patients in our study was higher than that observed in the general population of our country, the prevalence of MetS did not increase when compared to the similar age group. MetS was thought to be related to age and gender predominance rather than the disease itself. Although mRSS was found to be significantly lower in patients with MetS, its sensitivity to predict MetS was found to be low. Nevertheless, our data suggest that the risk of MetS should be considered in SSc patients.
- 9 September 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (3) , 474-483
Open AccessPrevalence of metabolic syndrome patıents with systemic sclerosis
Objective: To determine the prevalence of metabolic syndrome (MetS) in Turkish systemic sclerosis (SSc) patients. Materials and Methods: In this cross-sectional, single-centre study, 76 SSc patients admitted to the outpatient clinic of our tertiary care hospital between July and September 2021 were included. The National Cholesterol Education Programme's Adult Treatment Panel (NCEP-ATP III) criteria were used to define metabolic syndrome (MetS). The relationship between MetS and SSc organ involvement and disease characteristics was investigated. Results: According to the ATP III criteria, 37 cases (48.7%) were identified as having MetS. The prevalance of MetS increased with advancing age (40-45 years: 25%, 46-60 years: 48.4%, >60 years: 62.9%). The cases were divided into two groups according to the presence or absence of MetS. Patients with MetS had higher mean age (58.2±9.4 vs. 51.6±13.5, p=0.015) and lower modified Rodnan skin scores (14 vs. 22, p=0.019). The groups were comparable regarding disease subtype, duration and activity, organs/systems involved and disease-related damage. Conclusion: Although the prevalence of MetS in SSc patients in our study was higher than that observed in the general population of our country, the prevalence of MetS did not increase when compared to the similar age group. MetS was thought to be related to age and gender predominance rather than the disease itself. Although mRSS was found to be significantly lower in patients with MetS, its sensitivity to predict MetS was found to be low. Nevertheless, our data suggest that the risk of MetS should be considered in SSc patients.
- Open Access
- 9 September 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (3) , 378-382
Pandemi döneminde subakut granülomatöz tiroidit
Amaç: Tiroidit, tiroit bezinin enflamasyonu ile karakterize, tiroid fonksiyon bozukluğuna yol açabilen, çoğunlukla benign seyreden bir klinik tablodur. Enfeksiyonlar akut tiroidit ve subakut granülomatöz tiroidit (SAT) etiyolojisinde yer alır. Ancak enfeksiyon etkenlerini saptamak her zaman mümkün olmamaktadır. Çalışmamızda Ege Üniversitesi Tıp Fakültesi Hastanesi’nde Endokrinoloji ve Metabolizma veya Enfeksiyon Hastalıkları Polikliniği’nde tiroidit tanısı ile takip edilen hastalar arasında SAT tanısı alan hastaların geriye dönük incelenmesi, SARS-CoV-2 enfeksiyonu veya SARS-CoV-2 aşısının etiyolojideki rolünün incelenmesi amaçlanmıştır. Gereç ve Yöntem: Çalışmanın evrenini Mart 2020 ve Temmuz 2023 tarihleri arasında ICD tanı kodu tiroidit olarak girilen hastalar oluşturmaktadır. Bu hastalar arasında SAT tanısı alan hastaların yaşı, cinsiyeti, eşlik eden hastalıkları, SARS-CoV-2’ ye karşı aşılanma öyküleri, tiroidit ile ilişkili klinik yakınmaları, yakınmalar öncesinde üst solunum yolu enfeksiyonu (ÜSYE), gastroenterit veya SARS-CoV-2 enfeksiyonu geçirme öyküsü, SAT tanısı aldığı tarih, laboratuvar ve görüntüleme bulguları, hastalara uygulanan tedaviler retrospektif olarak değerlendirilmiştir. Bulgular: Çalışmaya belirlenen tarihler arasında SAT tanısı alan 9 hasta dahil edilmiştir. Olguların yaş ortalaması 47,6 ± 7,3 (min. 39, maks. 58) ve hastaların altısı kadındır. En sık klinik yakınma boyun ve boğaz ağrısı, boğazda şişlik hissi ve ateş yüksekliği olarak saptanmıştır. Hastalardan ikisinde SAT tanısı almadan üç ay içerisinde SARS-CoV-2 aşısı öyküsü mevcuttur. ÜSYE öyküsü olan hastalardan birinde hem SARS-CoV-2 enfeksiyonu hem de aşı öyküsü vardır. Sonuç: Çalışmamızda sadece iki hastada SAT etiyolojisinde SARS-CoV-2 enfeksiyonu veya aşısı sorumlu olabileceği düşünülmüştür ancak diğer hastalarda ilişki bulunamamıştır. Hasta sayımız az olmakla birlikte elimizdeki veriler SARS-CoV-2 enfeksiyonu ve aşışı ile SAT ilişkisini ortaya koymak için yeterli değildir. Not: Poster bildirisi şeklinde 11. Türkiye EKMUD bilimsel kongresinde (3-7 Mayıs 2023, Girne, Kıbrıs) sunulmuştur.
- 9 September 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (3) , 378-382
Open AccessPandemi döneminde subakut granülomatöz tiroidit
Amaç: Tiroidit, tiroit bezinin enflamasyonu ile karakterize, tiroid fonksiyon bozukluğuna yol açabilen, çoğunlukla benign seyreden bir klinik tablodur. Enfeksiyonlar akut tiroidit ve subakut granülomatöz tiroidit (SAT) etiyolojisinde yer alır. Ancak enfeksiyon etkenlerini saptamak her zaman mümkün olmamaktadır. Çalışmamızda Ege Üniversitesi Tıp Fakültesi Hastanesi’nde Endokrinoloji ve Metabolizma veya Enfeksiyon Hastalıkları Polikliniği’nde tiroidit tanısı ile takip edilen hastalar arasında SAT tanısı alan hastaların geriye dönük incelenmesi, SARS-CoV-2 enfeksiyonu veya SARS-CoV-2 aşısının etiyolojideki rolünün incelenmesi amaçlanmıştır. Gereç ve Yöntem: Çalışmanın evrenini Mart 2020 ve Temmuz 2023 tarihleri arasında ICD tanı kodu tiroidit olarak girilen hastalar oluşturmaktadır. Bu hastalar arasında SAT tanısı alan hastaların yaşı, cinsiyeti, eşlik eden hastalıkları, SARS-CoV-2’ ye karşı aşılanma öyküleri, tiroidit ile ilişkili klinik yakınmaları, yakınmalar öncesinde üst solunum yolu enfeksiyonu (ÜSYE), gastroenterit veya SARS-CoV-2 enfeksiyonu geçirme öyküsü, SAT tanısı aldığı tarih, laboratuvar ve görüntüleme bulguları, hastalara uygulanan tedaviler retrospektif olarak değerlendirilmiştir. Bulgular: Çalışmaya belirlenen tarihler arasında SAT tanısı alan 9 hasta dahil edilmiştir. Olguların yaş ortalaması 47,6 ± 7,3 (min. 39, maks. 58) ve hastaların altısı kadındır. En sık klinik yakınma boyun ve boğaz ağrısı, boğazda şişlik hissi ve ateş yüksekliği olarak saptanmıştır. Hastalardan ikisinde SAT tanısı almadan üç ay içerisinde SARS-CoV-2 aşısı öyküsü mevcuttur. ÜSYE öyküsü olan hastalardan birinde hem SARS-CoV-2 enfeksiyonu hem de aşı öyküsü vardır. Sonuç: Çalışmamızda sadece iki hastada SAT etiyolojisinde SARS-CoV-2 enfeksiyonu veya aşısı sorumlu olabileceği düşünülmüştür ancak diğer hastalarda ilişki bulunamamıştır. Hasta sayımız az olmakla birlikte elimizdeki veriler SARS-CoV-2 enfeksiyonu ve aşışı ile SAT ilişkisini ortaya koymak için yeterli değildir. Not: Poster bildirisi şeklinde 11. Türkiye EKMUD bilimsel kongresinde (3-7 Mayıs 2023, Girne, Kıbrıs) sunulmuştur.
- 1 April 2024
- Published by Elsevier in Journal of Critical Care
- Vol. 82, 154804
Letter to the editor: "Heart involvement: A neglected manifestation of haemophagocytic syndrome associated with high mortality"
- 1 April 2024
- Published by Elsevier in Journal of Critical Care
- Vol. 82, 154804
Letter to the editor: "Heart involvement: A neglected manifestation of haemophagocytic syndrome associated with high mortality"
- 30 November 2023
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (1) , 106-114
Pandemi öncesi ve pandemi döneminde acil servisten iç hastalıkları yoğun bakım ünitesine yatan COVID-19 dışı kritik hastaların karşılaştırılması
- 30 November 2023
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (1) , 106-114
Pandemi öncesi ve pandemi döneminde acil servisten iç hastalıkları yoğun bakım ünitesine yatan COVID-19 dışı kritik hastaların karşılaştırılması
- Open Access
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 419-428
Efficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases
Objectives: In this study, we report the immune response to the BNT162b2 vaccine and CoronaVac vaccine after a two-dose vaccination and the effects of conventional drugs, immunosuppressive drugs, and new-generation therapies on vaccine responses in patients with rheumatic and musculoskeletal diseases (RMDs). Patients and methods: This is a prospective observational study conducted with 94 patients (65 males, 29 females; mean age: 42.7±12.1 years; range, 19 to 69 years) between May 2021 and January 2022. The immunogenicity of the two-dose regimens of the BNT162b2 and CoronaVac vaccines in adult patients with RMD was analyzed according to disease and treatments. Serum immunoglobulin G antibody levels against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike proteins were measured four weeks after the second dose of vaccines. Results: Patients on regimens including mycophenolate, rituximab, and steroids were less likely to develop an antibody response (p=0.001, p=0.06, and p=0.001, respectively). Impairment of vaccine response by other conventional disease-modifying antirheumatic drugs and by anti-tumor necrosis factor treatments was not shown. Younger participants appeared more likely to develop an antibody response. The CoronaVac vaccine was less likely to develop an antibody response compared to the BNT162b2 vaccine (p=0.002). Systemic lupus erythematosus and vasculitis had the lowest antibody titers compared to other RMDs. Conclusion: Patients receiving mycophenolate mofetil, rituximab, and steroids should be warned about the risk of a suboptimal vaccine response. If possible, vaccination strategies should be changed, and the dose modification of drugs should be made during the vaccination. Further studies are required to determine the responses to SARS-CoV-2 vaccination and optimization of vaccine response in patients with RMDs.
- 30 September 2023
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 38 (3) , 419-428
Open AccessEfficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases
Objectives: In this study, we report the immune response to the BNT162b2 vaccine and CoronaVac vaccine after a two-dose vaccination and the effects of conventional drugs, immunosuppressive drugs, and new-generation therapies on vaccine responses in patients with rheumatic and musculoskeletal diseases (RMDs). Patients and methods: This is a prospective observational study conducted with 94 patients (65 males, 29 females; mean age: 42.7±12.1 years; range, 19 to 69 years) between May 2021 and January 2022. The immunogenicity of the two-dose regimens of the BNT162b2 and CoronaVac vaccines in adult patients with RMD was analyzed according to disease and treatments. Serum immunoglobulin G antibody levels against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike proteins were measured four weeks after the second dose of vaccines. Results: Patients on regimens including mycophenolate, rituximab, and steroids were less likely to develop an antibody response (p=0.001, p=0.06, and p=0.001, respectively). Impairment of vaccine response by other conventional disease-modifying antirheumatic drugs and by anti-tumor necrosis factor treatments was not shown. Younger participants appeared more likely to develop an antibody response. The CoronaVac vaccine was less likely to develop an antibody response compared to the BNT162b2 vaccine (p=0.002). Systemic lupus erythematosus and vasculitis had the lowest antibody titers compared to other RMDs. Conclusion: Patients receiving mycophenolate mofetil, rituximab, and steroids should be warned about the risk of a suboptimal vaccine response. If possible, vaccination strategies should be changed, and the dose modification of drugs should be made during the vaccination. Further studies are required to determine the responses to SARS-CoV-2 vaccination and optimization of vaccine response in patients with RMDs.